These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 67089)

  • 41. Formation of high-affinity C5 convertases of the alternative pathway of complement.
    Rawal N; Pangburn M
    J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN).
    Geiger H; Good RA; Day NK
    Clin Nephrol; 1975; 3(4):139-47. PubMed ID: 1149337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.
    Takahashi M; Tack BF; Nussenzweig V
    J Exp Med; 1977 Jan; 145(1):86-100. PubMed ID: 830792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of the alternative pathway of complement in the newborn infant.
    Adamkin D; Stitzel A; Urmson J; Farnett ML; Post E; Spitzer R
    J Pediatr; 1978 Oct; 93(4):604-8. PubMed ID: 702236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
    Day NK; Schreiber RD; Götze O; Müller-Eberhard HJ
    Scand J Immunol; 1976; 5(6-7):715-20. PubMed ID: 981969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Complement activation and biological activities].
    Inoue K
    Nihon Saikingaku Zasshi; 1976 Jul; 31(4):535-55. PubMed ID: 988219
    [No Abstract]   [Full Text] [Related]  

  • 47. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
    Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum complement components in patients with trachoma.
    Sen DK; Sarin GS; Hiranandani M; Baveja UK
    Br J Ophthalmol; 1985 Sep; 69(9):707-10. PubMed ID: 3876110
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
    Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
    J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 52. Participation of an early component of complement and Hageman factor in C3 destruction by zymosan.
    Gigli I; Koethe S; Austen KF
    Clin Immunol Immunopathol; 1975 Jul; 4(2):189-98. PubMed ID: 1170051
    [No Abstract]   [Full Text] [Related]  

  • 53. Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway.
    Theofilopoulos AN; Perrin LH
    Science; 1977 Mar; 195(4281):878-80. PubMed ID: 402691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation.
    Giclas PC; King TE; Baker SL; Russo J; Henson PM
    Am Rev Respir Dis; 1987 Feb; 135(2):403-11. PubMed ID: 3643768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of properdin in the alternate pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    J Exp Med; 1974 Jan; 139(1):44-57. PubMed ID: 4808709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
    Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
    Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.
    Freeley SJ; Popat RJ; Parmar K; Kolev M; Hunt BJ; Stover CM; Schwaeble W; Kemper C; Robson MG
    J Pathol; 2016 Sep; 240(1):61-71. PubMed ID: 27235854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The human complement system.
    Volanakis JE
    J Oral Pathol; 1975; 4(4):195-221. PubMed ID: 811779
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.